NCT01383759 · OUTCOME

Progression Free Survival at 24 Months

Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis · Source last updated 2020-04-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: percentage of patients
Interval / dispersion: 95% Confidence Interval
Time frame: 24 months

What was measured

following the 3-phase comprehensive treatment approach including induction with BD, followed by risk adapted HDM/ASCT, followed by consolidation/maintenance therapy with BD in patients with AL amyloidosis.

Groups in this outcome

Amyloidosis

Participants with newly diagnosed AL amyloidosis

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Amyloidosis	19

Reported measurements

Source class 1

Values in percentage of patients · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Amyloidosis	68	Not reported	50	93	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
50
upper Limit
93
value
68

denoms

counts
group Id
OG000
value
19
units
Participants

description

dispersion Type

95% Confidence Interval

groups

description
Participants with newly diagnosed AL amyloidosis
id
OG000
title
Amyloidosis

param Type

NUMBER

reporting Status

POSTED

time Frame

24 months

title

Progression Free Survival at 24 Months

type

SECONDARY

unit Of Measure

percentage of patients

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice